53 related articles for article (PubMed ID: 1301675)
21. Sensorineural hearing loss after treatment of nasopharyngeal carcinoma: a longitudinal analysis.
Chan SH; Ng WT; Kam KL; Lee MC; Choi CW; Yau TK; Lee AW; Chow SK
Int J Radiat Oncol Biol Phys; 2009 Apr; 73(5):1335-42. PubMed ID: 18922648
[TBL] [Abstract][Full Text] [Related]
22. [Experimental study on the use of cisplatin in oncology].
Scanni A; Tomirotti M; Campolunghi D; Biraghi M; Curtarelli G
Minerva Med; 1985 Apr; 76(17-18):851-7. PubMed ID: 3889721
[TBL] [Abstract][Full Text] [Related]
23. Cisplatin vestibular ototoxicity: preliminary report.
Black FO; Myers EN; Schramm VL; Johnson J; Sigler B; Thearle PB; Burns DS
Laryngoscope; 1982 Dec; 92(12):1363-8. PubMed ID: 6983636
[TBL] [Abstract][Full Text] [Related]
24. [Clinical study on the ototoxicity of cisplatin with distortion products].
Orts Alborch M; García Callejo J; Morant Ventura A; Ferrer Baixauli F; Esparcia Navarro M; Marco Algarra J
Acta Otorrinolaringol Esp; 2000; 51(6):469-77. PubMed ID: 11142781
[TBL] [Abstract][Full Text] [Related]
25. [Clinical efficacy of GG032X tablets, a new dosage form of ondansetron (fast dispersing tablet), on cisplatin-induced nausea and emesis].
Ariyoshi Y; Nukariya N; Akasaka Y; Suminaga M; Ota J; Ikeda M; Taguchi T
Gan To Kagaku Ryoho; 1997 Jun; 24(8):995-1011. PubMed ID: 9212810
[TBL] [Abstract][Full Text] [Related]
26. Ototoxicity of high-dose cisplatin by bolus administration in patients with advanced cancers and normal hearing.
Kopelman J; Budnick AS; Sessions RB; Kramer MB; Wong GY
Laryngoscope; 1988 Aug; 98(8 Pt 1):858-64. PubMed ID: 3398663
[TBL] [Abstract][Full Text] [Related]
27. Case report: two cases of hearing impairment due to intracranial hypotension.
Taki M; Nin F; Hasegawa T; Sakaguchi H; Yamamoto S; Suzuki T; Hisa Y
Auris Nasus Larynx; 2009 Jun; 36(3):345-8. PubMed ID: 18774246
[TBL] [Abstract][Full Text] [Related]
28. The role of low dose cisplatin plus 5-fluorouracil for treatment of recurrent and/or advanced squamous cell carcinoma of the head and neck.
Kohno N; Kitahara S; Tamura E; Tanabe T; Nakanoboh M; Kawada M; Shirasaka T
Gan To Kagaku Ryoho; 2000 May; 27 Suppl 2():592-9. PubMed ID: 10895216
[TBL] [Abstract][Full Text] [Related]
29. [Concurrent chemoradiotherapy (CRT) with S-1 and cisplatin (CDDP) in patients (pts) with locally advanced head and neck cancer (HNC)].
Tahara M
Gan To Kagaku Ryoho; 2006 Jun; 33 Suppl 1():167-71. PubMed ID: 16897996
[TBL] [Abstract][Full Text] [Related]
30. Feasibility trial of postoperative radiotherapy and cisplatin followed by three courses of 5-FU and cisplatin in patients with resected head and neck cancer: a Southwest Oncology Group study.
Kish JA; Benedetti JK; Balcerzak SP; Veith RW; Davis R; Pollock TW; Schuller DE; Ensley JF
Cancer J Sci Am; 1999; 5(5):307-11. PubMed ID: 10526672
[TBL] [Abstract][Full Text] [Related]
31. Recent advances in paclitaxel-containing chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck.
Shin DM; Glisson BS; Khuri FR; Ginsberg L; Lawhorn K; Hong WK; Lippman SM
Semin Oncol; 1997 Dec; 24(6 Suppl 19):S19-33-S19-37. PubMed ID: 9427263
[TBL] [Abstract][Full Text] [Related]
32. [Cisplatin and carboplatin-induced ototoxicity in children: clinical aspects and perspectives for prevention].
Montaguti M; Brandolini C; Ferri GG; Hatzopoulos S; Prete A; Pession A
Acta Otorhinolaryngol Ital; 2002 Feb; 22(1):14-8. PubMed ID: 12236007
[TBL] [Abstract][Full Text] [Related]
33. Paclitaxel and cisplatin in patients with recurrent and metastatic head and neck squamous cell carcinoma.
Adamo V; Ferraro G; Pergolizzi S; Sergi C; Laudani A; Settineri N; Alafaci E; Scimone A; Spano F; Spitaleri G
Oral Oncol; 2004 May; 40(5):525-31. PubMed ID: 15006626
[TBL] [Abstract][Full Text] [Related]
34. Adjuvant docetaxel, cisplatin and 5-fluorouracil (TPF) in locally advanced squamous cell carcinoma of the head and neck.
Baghi M; Hambek M; May A; Radeloff A; Gstoettner W; Knecht R
Anticancer Res; 2006; 26(1B):559-63. PubMed ID: 16739320
[TBL] [Abstract][Full Text] [Related]
35. Cisplatin, fluorouracil, and leucovorin induction chemotherapy followed by concurrent cisplatin chemoradiotherapy for organ preservation and cure in patients with advanced head and neck cancer: long-term follow-up.
Psyrri A; Kwong M; DiStasio S; Lekakis L; Kassar M; Sasaki C; Wilson LD; Haffty BG; Son YH; Ross DA; Weinberger PM; Chung GG; Zelterman D; Burtness BA; Cooper DL
J Clin Oncol; 2004 Aug; 22(15):3061-9. PubMed ID: 15284256
[TBL] [Abstract][Full Text] [Related]
36. Hearing loss due to concurrent daily low-dose cisplatin chemoradiation for locally advanced head and neck cancer.
Zuur CL; Simis YJ; Verkaik RS; Schornagel JH; Balm AJ; Dreschler WA; Rasch CR
Radiother Oncol; 2008 Oct; 89(1):38-43. PubMed ID: 18706728
[TBL] [Abstract][Full Text] [Related]
37. [The ototoxicity of cisplatin in the chemotherapy of tumors of the head-neck area. Our experience].
Sbalzarini G; Malusardi G; Pandolfi C; Cerri A
Minerva Med; 1990 May; 81(5):403-5. PubMed ID: 2377307
[TBL] [Abstract][Full Text] [Related]
38. Paclitaxel, cisplatin, and 5-fluorouracil for patients with advanced or recurrent squamous cell carcinoma of the head and neck.
Hussain M; Gadgeel S; Kucuk O; Du W; Salwen W; Ensley J
Cancer; 1999 Dec; 86(11):2364-9. PubMed ID: 10590379
[TBL] [Abstract][Full Text] [Related]
39. Short-term cohort study on sensorineural hearing changes in head and neck radiotherapy.
Cheraghi S; Nikoofar P; Fadavi P; Bakhshandeh M; Khoie S; Gharehbagh EJ; Farahani S; Mohebbi A; Vasheghani M; Zare M; Nikoofar A; Mahdavi SR
Med Oncol; 2015 Jul; 32(7):200. PubMed ID: 26071124
[TBL] [Abstract][Full Text] [Related]
40. [Center for the Study of the Chemistry of Plasma, Bari].
Molinari E
Ric Sci; 1970; 40(4):284. PubMed ID: 5500890
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
